Hosken Consolidated Inv Stock (OTC: HKCIF)

Latest news for Hosken Consolidated Inv (OTC:HKCIF) Stock

Hosken Consolidated Investments Ltd is an investment holdings company. The group is involved in a diverse group of investments including Media and broadcasting; Gaming; Transport; Properties; Coal mining; Branded products and manufacturing and other. It generates maximum revenue from the Branded products and manufacturing segment.

HOSKEN CONS INV LTD by Hosken Consolidated Investments Ltd.

Hosken Consolidated Investments Ltd

<p><strong>Alex Fazel</strong>, Chief Partnership Officer at Swissborg, sees <strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) as the "best Trump proxy", highlighting its potential to <a href="https://www.benzinga.com/general/education/24/11/41882342/heres-how-much-100-in-dogecoin-today-could-be-worth-if-doge-hits-new-all-time-highs-2#:~:text=If%20Dogecoin%20can%20return%20to,more%20%E2%80%9CMuch%20Wow%E2%80%9D%20moments.">reach one dollar</a>.</p>
<p><strong>What Happened: </strong>Fazel shared his portfolio in a <a href="https://x.com/tradetheflow_/status/1856290955244253659">post</a> on <strong>X</strong>, saying that meme coins make up a small and speculative portion of his holdings, while his primary investments are <strong>Bitcoin</strong>, <strong>Solana</strong>, <strong>Ethereum</strong> and a few DeFi and AI projects.</p>
<p>Fazel sees <strong>Goatseus Maximus </strong>(CRYPTO: GOAT) as an "OG meme" with staying power, recently gaining a Bybit listing and potentially a Binance spot listing soon.</p>
<p>His other meme holdings include <strong>Popcat </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>), <strong>Toshi</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TOSHI</a>) and <strong>Peanut The Squirrel</strong> (CRYPTO: PNUT) as a rising mascot meme. Toshi and Popcat are each &#8220;backed by strong communities,&#8221; according to the expert. </p>
<p>He predicted, "After a long period of consolidation, the chart also looks ready to send."</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41912787/buckle-up-for-the-bull-markets-most-fun-phase-says-industry-expert-bitcoin-ethereum-dogecoin-about-to-enter-the-euphoria-stage">&#8216;Buckle Up&#8217; For The Bull Market&#8217;s &#8216;Most Fun Phase,&#8217; Says Industry Expert: Bitcoin, Ethereum, Dogecoin About To Enter The &#8216;Euphoria&#8217; Stage</a></strong></p>
<p>The expert provides insight into the meme coin market, which has seen significant growth and volatility in recent years. His tweet serves as a reminder of the potential upside in the meme coin market, despite its inherent risks and volatility.</p>
<p><strong>Price Action: </strong>Dogecoin is up 20% over the past 24 hours, trading at 38 cents.</p>
<p><strong>What&#8217;s Next</strong>: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41876486/dogecoin-explodes-for-86-weekly-gain-what-is-going-on">Dogecoin Explodes For 86% Weekly Gain: What Is Going On?</a></strong></li>
</ul>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$DOGE

$POPCAT

$TOSHI

Dogecoin Is The 'Best Trump Proxy,' Industry Expert Claims

<p><strong>UnitedHealth Group Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company&#8217;s multi-billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32716991/optums-decision-to-target-amedisys-is-intriguing-says-analyst">acquisition of <strong>Amedisys Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>)</a>.</p>
<p><strong>What To Know:</strong> The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns related to competition in the home health services market, according to <a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738">The Wall Street Journal</a>.</p>
<p>Antitrust enforcers are concerned that a potential business combination could cause healthcare price increases in the areas where Amedisys competes with UnitedHealth's LHC Group.</p>
<p>&#8220;Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families and nurses," Assistant Attorney General&nbsp;<strong>Jonathan Kanter</strong>&nbsp;said.</p>
<p>The Justice Department reportedly filed the complaint in Maryland federal court, supported by state attorneys general of Maryland, Illinois, New Jersey and New York. </p>
<p>The report indicates that UnitedHealth and Amedisys executives met with the Justice Department last week, aiming to ease concerns. The companies proposed selling some of their other assets to VitalCaring Group.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a></strong></p>
<p>UnitedHealth entered into an agreement to acquire Amedisys last year. At the time, analysts raised concerns that the deal was likely to face scrutiny given the company&#8217;s robust home healthcare presence.</p>
<p>United Health bought LHC Group for about $5.4 billion in 2022. Amedisys is a main competitor&nbsp;to UnitedHealth&#8217;s LHC Group. Amedisys shares were down 2.21% at $90.54 at last check.</p>
<p><strong>UNH Price Action:</strong> UnitedHealth shares were down 1.18% at $617.85 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: courtesy of UnitedHealth.</em></p>


Legal

Movers

AMED

Justice Department Moves To Block UnitedHealth's Amedisys Takeover: What's Going On?

WIIM

Nano Labs shares are trading higher. Yesterday the company said it will start accepting payments in Bitcoin.

MNDY

Monday.com shares are trading lower. DA Davidson and Baird maintained Neutral ratings on the stock.

Global

Trading Ideas

AAPL

'Recent Market Rumor Suggests That Apple Is Looking To Hon Hai (Foxconn) To Manufacture AI Servers' - DigiTimes Alert

<p><a href="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power" title="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power">https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power</a>
</p><p><a href="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power" title="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power">https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power</a></p>


LTBR

OKLO

Reported Earlier: 'White House plan would provide huge boost for nuclear power' -Axios

<p>Deep-pocketed investors have adopted a bearish approach towards Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FICO usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Fair Isaac. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 7% leaning bullish and 53% bearish. Among these notable options, 2 are puts, totaling $67,500, and 11 are calls, amounting to $519,907.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1290.0 to $2460.0 for Fair Isaac over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Fair Isaac stands at 55.14, with a total volume reaching 17.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Fair Isaac, situated within the strike price corridor from $1290.0 to $2460.0, throughout the last 30 days.</p>
<h3>Fair Isaac 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731440855_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1067.0</td>
<td>$1057.8</td>
<td>$1057.8</td>
<td>$1290.00</td>
<td>$105.7K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$838.5</td>
<td>$830.0</td>
<td>$830.0</td>
<td>$1550.00</td>
<td>$83.0K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$487.9</td>
<td>$478.0</td>
<td>$483.0</td>
<td>$2150.00</td>
<td>$48.3K</td>
<td align="right">0</td>
<td align="right">6</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$220.9</td>
<td>$213.0</td>
<td>$215.0</td>
<td>$2200.00</td>
<td>$43.0K</td>
<td align="right">30</td>
<td align="right">2</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$392.0</td>
<td>$388.2</td>
<td>$392.0</td>
<td>$2000.00</td>
<td>$39.2K</td>
<td align="right">320</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
</p>
<h3>About Fair Isaac</h3>
<p>Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.</p>
<p>Having examined the options trading patterns of Fair Isaac, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Fair Isaac</h3>
<ul>
<li>Currently trading with a volume of 69,391, the FICO's price is down by 0.0%, now at $2350.0. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 72 days.</li>
</ul>
<h3>Professional Analyst Ratings for Fair Isaac</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $2252.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $2040.<br />
&#x2A; An analyst from Baird persists with their Neutral rating on Fair Isaac, maintaining a target price of $2000.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on Fair Isaac, maintaining a target price of $2350.<br />
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Fair Isaac, maintaining a target price of $2374.<br />
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Fair Isaac, which currently sits at a price target of $2500. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Fair Isaac options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

FICO

Check Out What Whales Are Doing With FICO

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>MongoDB</strong>.</p>
<p>Looking at options history for MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 8 are puts, for a total amount of $384,622 and 2, calls, for a total amount of $143,050.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $300.0 for MongoDB over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for MongoDB's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across MongoDB's significant trades, within a strike price range of $210.0 to $300.0, over the past month.</p>
<h3>MongoDB 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731440849_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MDB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$48.25</td>
<td>$46.0</td>
<td>$46.0</td>
<td>$260.00</td>
<td>$115.0K</td>
<td>341</td>
<td align="right">25</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$32.35</td>
<td>$32.35</td>
<td>$300.00</td>
<td>$100.2K</td>
<td>785</td>
<td align="right">35</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.1</td>
<td>$21.05</td>
<td>$21.05</td>
<td>$270.00</td>
<td>$71.5K</td>
<td>32</td>
<td align="right">105</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.87</td>
<td>$1.24</td>
<td>$1.5</td>
<td>$280.00</td>
<td>$45.0K</td>
<td>1.7K</td>
<td align="right">303</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.2</td>
<td>$26.5</td>
<td>$27.2</td>
<td>$270.00</td>
<td>$40.8K</td>
<td>159</td>
<td align="right">21</td>
</tr>
</tbody>
</table>
</p>
<h3>About MongoDB</h3>
<p>Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.</p>
<p>Following our analysis of the options activities associated with MongoDB, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is MongoDB Standing Right Now?</h3>
<ul>
<li>With a trading volume of 610,507, the price of MDB is up by 0.83%, reaching $294.0.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MongoDB options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Market Whales and Their Recent Bets on MDB Options

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Unity Software</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with U, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for <strong>Unity Software</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 30% bullish and 70%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $37,635, and 9, calls, for a total amount of $664,840.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $30.0 for Unity Software, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Unity Software's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Unity Software's significant trades, within a strike price range of $10.0 to $30.0, over the past month.</p>
<h3>Unity Software Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731440845_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.7</td>
<td>$2.5</td>
<td>$2.58</td>
<td>$30.00</td>
<td>$221.8K</td>
<td>6.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.85</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$14.00</td>
<td>$86.2K</td>
<td>770</td>
<td>151</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.72</td>
<td>$0.71</td>
<td>$0.7</td>
<td>$22.00</td>
<td>$82.6K</td>
<td>4.0K</td>
<td>1.7K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.75</td>
<td>$2.66</td>
<td>$2.66</td>
<td>$30.00</td>
<td>$79.8K</td>
<td>6.3K</td>
<td>316</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.05</td>
<td>$1.99</td>
<td>$2.05</td>
<td>$20.00</td>
<td>$61.5K</td>
<td>20.1K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Unity Software</h3>
<p>Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.</p>
<h3>Where Is Unity Software Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 6,161,737, the U's price is down by -3.86%, now at $19.42. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 104 days.</li>
</ul>
<h3>What Analysts Are Saying About Unity Software</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $19.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Unity Software, targeting a price of $20.<br />
&#x2A; An analyst from Wells Fargo downgraded its action to Equal-Weight with a price target of $20.<br />
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Unity Software, targeting a price of $26.<br />
&#x2A; Maintaining their stance, an analyst from Macquarie continues to hold a Underperform rating for Unity Software, targeting a price of $16.<br />
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Sell rating for Unity Software, targeting a price of $15. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Unity Software options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With Unity Software

IBRX

ImmunityBio shares are trading higher after the company reported better-than-expected Q3 financial results. D.Boral maintained a Buy rating on the stock.

CGON

CG Oncology shares are trading lower. The company reported Q3 financial results.

IAC shares are trading lower following Q3 financial results.

Agilon Health shares are trading lower after Stifel cut its price target on the stock from $7 to $2.

<p>Activist JCP Investment Management is proposing a spinoff of some brands.</p>
<p><br /><a href="https://www.axios.com/pro/retail-deals/2024/11/12/cheesecake-factory-jcp-strategic-pe-buyers" title="https://www.axios.com/pro/retail-deals/2024/11/12/cheesecake-factory-jcp-strategic-pe-buyers">https://www.axios.com/pro/retail-deals/2024/11/12/cheesecake-factory-jcp-strategic-pe-buyers</a></p>


CAKE

'Cheesecake Factory's strategic options for its smaller brands' - Axios

ABSI

Absci shares are trading lower after the company reported worse-than-expected Q3 financial results.

ASPN

Aspen Aerogels shares are trading lower after Barclays cut its price target on the stock from $27 to $25.

TIGR

UP Fintech shares are trading lower after the company reported worse-than-expected Q3 adjusted EPADS results.

DADA

Dada Nexus shares are trading lower. Mizuho cut its price target on the stock from $4.5 to $4.

<p>Recent innovations in <a href="https://www.benzinga.com/topic/psychedelics-research">psychedelics research</a> are laying the groundwork for a potential breakthrough in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">mental health treatments</a>. The focus is on three new compounds patented by <strong>CaaMTech, Inc.</strong>, designed to address the limitations of traditional psychedelics such as <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/psilocin">psilocin</a>. </p>
<p>According to a <a href="https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00519">patent review</a> published by the American Chemical Society, the new compounds promise improved stability, bioavailability and therapeutic efficacy for conditions such as depression, anxiety and substance use disorders.</p>
<h3 class="wp-block-heading">Revolutionizing Psilocin Delivery: A New Approach </h3>
<p>A groundbreaking patent, <a href="https://patents.google.com/patent/US20230406823A1/en?oq=US+2023%2f0406823+A1">US 2023/0406823 A1</a>, introduces a new compound called <strong>4-pivaloyloxy-N-methyltryptammonium chloride</strong>, designed to solve some of the biggest challenges in using psilocin for therapeutic purposes. Psilocin, a chemical related to psilocybin, the psychoactive compound in <a href="https://www.benzinga.com/topic/magic-mushrooms">magic mushrooms</a>, affects mood, perception and cognition by interacting with serotonin receptors in the brain. However, psilocin is unstable, which has limited its use in medicine.</p>
<p>The key innovation here is a stable form of psilocin that, when taken, is gradually broken down into active psilocin in the body. This prodrug allows for a controlled release of its effects, making it easier to use in medical treatments. Early studies show that this new compound is more stable and easier for the body to absorb, making it a promising option for consistent therapeutic effects. It could also improve patient adherence to treatment, especially in oral forms of medication.</p>
<h3 class="wp-block-heading">Improving Stability And Effectiveness: Alkyl Quaternary Ammonium Tryptamines</h3>
<p>Another important patent, <a href="https://patents.google.com/patent/US20240116867A1/en?oq=US+2024%2f0116867+A1">US 2024/0116867 A1</a>, presents a new group of compounds called <strong>alkyl quaternary ammonium tryptamines</strong>. These compounds are designed to be more stable and easier to dose than traditional psilocybin. By modifying the chemical structure, these compounds bind more effectively to serotonin receptors, especially the 5-HT2A receptor, which is responsible for the psychoactive effects of psychedelics.</p>
<p>Preclinical research shows that these new compounds retain the therapeutic benefits of psilocybin but have better pharmacokinetic properties, meaning they are absorbed, distributed and broken down by the body in a more controlled way. They could become valuable alternatives to traditional psychedelics, offering improved stability and effectiveness for mental health treatments.</p>
<h3 class="wp-block-heading">Advancing Prodrug Technologies: 4-Pivaloyloxy-N-Methyltryptammonium Derivatives</h3>
<p>Another patent, <a href="https://patents.google.com/patent/WO2023240104A1/en?oq=WO+2023%2f240104+A1">WO 2023/240104 A1</a>, goes further into developing variations of <strong>4-pivaloyloxy-N-methyltryptammonium</strong> compounds as prodrugs for psilocin and similar substances. These derivatives are engineered to improve how well the body absorbs and utilizes the active ingredients, ensuring a more predictable and consistent response to treatment.</p>
<p>These advancements aim to address issues like rapid breakdown of the drug and inconsistent absorption, which can make therapeutic use of psilocin unpredictable. The goal is to create prodrugs that provide more reliable, controlled outcomes, especially in treating serious mental health conditions.</p>
<h3 class="wp-block-heading"><strong>Implications For Psychedelic-Assisted Therapy</strong></h3>
<p>These patent innovations represent a major step forward in psychedelic therapy by improving how psilocin and related compounds are absorbed and processed in the body. Early studies show promising results, suggesting these new drugs could offer more effective and reliable treatments for mental health and neurological conditions. As research progresses, these breakthroughs may transform mental health care, providing new hope for patients with treatment-resistant conditions. The focus on improving stability, bioavailability and effectiveness underscores the importance of continued innovation in psychedelic medicine.</p>
<h3 class="wp-block-heading">Moving Toward Clinical Trials</h3>
<p>While the early research is promising, the next step is to conduct thorough clinical trials to test the compounds&#8217; safety and effectiveness in humans. Encouraging results so far suggest that these new prodrugs could represent a fresh type of therapy that combines the benefits of traditional medications with the potential of psychedelic-assisted treatments.</p>
<h3 class="wp-block-heading">Industry Outlook</h3>
<p>The increasing number of patent filings and breakthroughs in psychedelic research reflects growing interest in new mental health treatments. Companies are developing innovative compounds that could revolutionize the treatment of mental and neurological conditions. By focusing on prodrugs and chemical derivatives, these advancements aim to overcome the challenges that have limited psychedelics&#8217; medical use. Improved stability and bioavailability could make these new compounds viable alternatives to current treatments, especially for conditions that are difficult to manage with existing medications.</p>
<p><em>Cover image made with AI</em></p>


Cannabis

Psychedelics

Health Care

Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments

<p>Deep-pocketed investors have adopted a bullish approach towards FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FDX usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for FedEx. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $204,822, and 4 are calls, amounting to $180,133.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $300.0 for FedEx, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of FedEx stands at 797.71, with a total volume reaching 408.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in FedEx, situated within the strike price corridor from $240.0 to $300.0, throughout the last 30 days.</p>
<h3>FedEx Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731439895_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$16.25</td>
<td>$15.75</td>
<td>$15.75</td>
<td>$250.00</td>
<td>$92.9K</td>
<td>325</td>
<td align="right">59</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.25</td>
<td>$14.2</td>
<td>$14.25</td>
<td>$290.00</td>
<td>$61.1K</td>
<td>2.7K</td>
<td align="right">293</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$32.2</td>
<td>$31.6</td>
<td>$31.92</td>
<td>$290.00</td>
<td>$47.8K</td>
<td>141</td>
<td align="right">15</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.9</td>
<td>$21.5</td>
<td>$21.9</td>
<td>$300.00</td>
<td>$41.6K</td>
<td>1.5K</td>
<td align="right">24</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$52.05</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$290.00</td>
<td>$41.2K</td>
<td>35</td>
<td align="right">15</td>
</tr>
</tbody>
</table>
</p>
<h3>About FedEx</h3>
<p>FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.</p>
<p>In light of the recent options history for FedEx, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of FedEx</h3>
<ul>
<li>With a trading volume of 610,647, the price of FDX is up by 0.38%, reaching $290.9.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>What Analysts Are Saying About FedEx</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $331.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for FedEx, targeting a price of $331. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for FedEx, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Comments

Hosken Consolidated Inv

News

Latest news for Hosken Consolidated Inv (OTC:HKCIF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga